...
首页> 外文期刊>Experimental and clinical endocrinology and diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association >Expression of TIGIT and FCRL3 is Altered in T Cells from Patients with Distinct Patterns of Chronic Autoimmune Thyroiditis
【24h】

Expression of TIGIT and FCRL3 is Altered in T Cells from Patients with Distinct Patterns of Chronic Autoimmune Thyroiditis

机译:TIGIT和FCR13的表达在来自慢性自身免疫甲状腺炎患者的患者的T细胞中改变了患者

获取原文
获取原文并翻译 | 示例

摘要

Background Co-inhibitory receptors (IR), such as TIGIT and FCRL3, provide a checkpoint against highly destructive immune responses. Co-expression of TIGIT and FCRL3, in particular, has been linked to the HELIOS+ subset of regulatory CD4(+) FOXP3(+) T-cells. Of these, CD4(+) FOXP3-exon(E)2(+) cells have higher expression of IR and exhibit strongest suppressive properties. Nevertheless, how the expression of TIGIT, FCRL3, HELIOS, and FOXP3E2 is regulated in chronic autoimmune thyroiditis (AT), is not known.
机译:背景技术Co-抑制受体(例如TIGIT和FCRL3)提供了针对高度破坏性免疫应答的检查点。 特别是TIGIT和FCR13的共表达与调节CD4(+)FOXP3(+)T细胞的Helios +子集合。 其中,CD4(+)Foxp3-Exon(e)2(+)细胞具有更高的IR表达并表现出最强的抑制性能。 然而,如何在慢性自身免疫甲状腺炎(AT)中调节TIGIT,FCRL3,Helios和FoxP3E2的表达方式,是不知道的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号